reorder-banner-v6-tfs

The Thermo Fisher Scientific Accula system is a rapid diagnostic point of care platform that provides simple, accurate sample-to-answer rapid PCR. Using a palm-sized Accula Dock in a CLIA waived environment, the Accula rapid PCR Tests provide reliable, qualitative PCR results in ~30 minutes.

Please fill out the form below to reorder your Accula SARS-CoV-2 test products.

Estimate the number of Accula docks (D2000) and Accula SARS-CoV-2 tests (COV4100) required to achieve your desired throughput.

Calculate

*
*
*
*
*
*
*
*
*
 Cardinal Health
 McKesson
 Henry Schein
 Fisher Healthcare
 NDC
 Other
 
 
 
 
 Please confirm you would like to receive marketing and promotional email messages about products and services from Thermo Fisher Scientific and its brands in accordance with our privacy statement.
By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Thermo Fisher Scientific Privacy Policy.
 
 

 

Calculate

Estimates for your SARS-CoV-2 testing program:

Estimated number of Accula Docks:

Kits Per Week (25 tests per kit):

Kits Per Month (25 tests per kit):

 

NOTE: Testing for the Accula SARS-CoV-2 Test is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The Accula SARS-CoV-2 Test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

The Accula SARS-CoV-2 Test has not been FDA cleared or approved but has been authorized for emergency use by the FDA for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

For Emergency Use Authorization (EUA) Only. For prescription use only. For in vitro diagnostic use.